Eli Lilly’s Donanemab Prevention Trial is Recruiting

K2 Med is recruiting for a new Phase 3 trial for Eli Lilly’s new Alzheimer’s drug donanemab. By: Simon Spichak K2 is screening possible trial participants for a Phase 3 clinical trial of an Alzheimer’s drug called donanemab. Donanemab is designed to target beta-amyloid plaques which clump in the brain and lead to inflammation that […]

Why Are Musical Memories the Last to Go in Alzheimer’s?

When it comes to music and the brain, there is a very special link. By: Simon Spichak When Tony Bennett’s family announced last February that he had Alzheimer’s disease, few could have guessed that the 94-year-old singer would still hold two major concerts — performing dozens of songs for huge audiences and recalling all the […]

Alzheon’s Experimental Alzheimer’s Pill Recruiting for Trials

K2 is recruiting for a new Phase 3 trial for Alzheon’s new drug, which aims to be the first oral disease-modifying therapy for Alzheimer’s. Open Trials Technology is ever-changing and constantly evolving.  If you are in search of professionals who will attend to your needs, you can’t go wrong with K2 Medical Research. Contact our […]

Why can’t the brain regrow neurons?

Alzheimer’s kills brain cells. Can we help the brain make new ones? By: Simon Spichak If you scrape your knee or break a bone, new cells repair the damage before you even know it. Other organs in the body are even better at regrowing themselves: The cells lining the gut regenerate every three to four […]